TrialsgrambetaRCTs are beautiful

CheckMate-577

2021

Adjuvant Nivolumab in Resected Oesophageal/GEJ Cancer

In 794 patients with resected oesophageal/GEJ cancer and residual pathologic disease after neoadjuvant chemoradiation, adjuvant nivolumab for one year improved disease-free survival compared with placebo.

Result

Efficacy: Disease-free survivalHR 0.69

Below 1 favours nivolumab for one year, above 1 favours placebo.

Event rates Nivolumab for one year 22.4 vs placebo 11.0 months

Also reported: Final OS 51.7 vs 35.3 months (HR 0.85; p=0.1064), not statistically significant.

Original publication
Subtopic
Oesophageal adjuvant
Design
Double-blind RCT
Relevance
Supporting: context rather than must-know.
Source
Kelly RJ, et al. N Engl J Med. 2021;384(13):1191-1203.doi 10.1056/NEJMoa2032125

Discussion & critique

DFS-positive but OS-not-significant: a recurrent pattern in adjuvant immunotherapy trials. Counsel patients accordingly.